Endo International Ordinary Shares reported $364.83M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Amarin AMRN:US USD 65.94M 7.31M
Ani Pharmaceuticals ANIP:US USD 50.93M 12.37M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Eli Lilly And LLY:US USD 5.36B 305M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Hikma Pharmaceutical HIK:LN USD 623M 62M
Horizon Pharma HZNP:US USD 691.23M 45.03M
Lannett LCI:US USD 12.6M 4.74M
Merk MRK:US USD 11.52B 1.08B
Novartis NOVN:VX USD 9.18B 151M
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Patterson Companies PDCO:US USD 328.09M 15.96M
Perrigo Ordinary Shares PRGO:US USD 362.9M 9.2M
Pfizer PFE:US USD 16.55B 2.52B
Revance Therapeutics RVNC:US USD 18.28M 566K
Takeda 4502:JP JPY 696.86B 17.28B
Teva Pharmaceutical TEVA:IT USD 1.71B 118M
Xeris Pharmaceuticals Inc XERS:US USD 24.46M 3.97M
Zoetis ZTS:US USD 1.4B 36M